Acute Lymphoblastic Leukemia, Acute Myeloblastic Leukemia, Chronic Myeloid Leukemia
Conditions
Keywords
recipient of a HSC graft in Acute Myeloblastic Leukemia therapy, recipient of a HSC graft in others pathologies treated in hematology of Nantes university hospital or Angers university hospital, donors are healthy subjects
Brief summary
Numerous studies about the potential role of NK alloreactive during a n hematopoietic stem cells graft are based on genotypical analyses of the KIR receptors and on genotypic incompatibilities between KIR and HLA for couple donor/recipient. There is still a lot of issues non resolved: Are KIR really expressed and how occur their expression during time when hematopoietic reconstitution? Is it depending on HLA of the recipient?If KIR are expressed, what are the mechanisms of alloreactivity of NK cells? Are NK able to lyse tumoral cells? Could alloreactive NK cells constitute a therapeutic tool able to induce tolerance and elimination of leukemia during hematopoietic stem cells grafts?
Interventions
PROCEDUREBlood test
The study of KIR and HLA genes will be performed on samples of cord blood or peripheral blood donor and recipient before transplant For grafts from placental cord blood, we do ask any additional samples.
Sponsors
Nantes University Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age superior to 1 year * Patient that will be treated by an HSC graft * Initial pathology of recipient: acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic myeloid leukemia
Exclusion criteria
* Patient already included in a study with an exclusion period * HIV + or HCV + serology during pre-graft analysis * Patient already treated by an allograft of HSC
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Estimate in the pilot study the percentage of different NK cell populations during hematopoietic reconstitution after HSCT with regard to the KIR and HLA genotypes of donor / recipient | J60 post-HSCT |
Secondary
| Measure | Time frame |
|---|---|
| Genetic analysis of KIR and HLA incompatibility of donor and recipient - Rate of in vitro amplification of NK cells from the donor - Assess the percentage of NK cells from the donor | J60 post-HSCT |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORFrançoise Mechinaud, md
Nantes University Hospital
PRINCIPAL_INVESTIGATORPatrice Chevallier, MD
Nantes University Hospital
PRINCIPAL_INVESTIGATORNadège Corradini, MD
Nantes University Hospital
PRINCIPAL_INVESTIGATORNorbert Ifrah, MD
University Hospital, Angers
Outcome results
None listed